Abstract
Objective: To determine if quetiapine, an atypical antipsychotic agent approved for the treatment of schizophrenia, is effective in the treatment of bipolar disorder.
Materials and Methods: A retrospective chart review identified six patients with DSM-IV bipolar disorder, type I, who received open uncontrolled treatment with quetiapine in the setting of nonresponse or intolerance to traditional mood-stabilizing treatments. Treatment response was based on moderate to marked improvement on the Clinical Global Impression-Bipolar Disorder (CGI-BP) scale.
Results: Two of six patients showed evidence of response. The main side effect noted was sedation.
Conclusions: Quetiapine may be a useful treatment for some patients with treatment-resistant bipolar disorder. Further studies are needed to assess quetiapine's effect more rigorously.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Calabrese JR, Kimmel SE, Woyshville MJ, et al.: Clozapine for treatment-refractory mania. American Journal of Psychiatry 1996; 153:759–764
Zarate CA, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clinical Psychiatry 1995; 56:411–417
Frankenburg FR: Clozapine and bipolar disorder. J-Clin-Psychopharmacol 1993; 13(4):289–90
Naber D, RH, CP, HH: Clinical management of clozapine patients in relation to efficacy and side-effects. British Journal of Psychiatry 1992; 160(suppl 17):54–59
McElroy SL, Dessain EC, Pope HG, et al.: Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clinical Psychiatry 1991; 52:411–414
Banov MD, Zarate CA, Tohen M, et al.: Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clinical Psychiatry 1994; 55:295–300
Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO: Clozapine in the treatment of dysphoric mania. Biol Psychiatry 1992; 32(3):270–280
Jacobsen FM: Risperidone in the treatment of affective illness and obsessive-compulsive disorder. Journal of Clinical Psychiatry 1995; 56:423–429
Tohen M, Zarate CA, Centorrino F, Hegary JI, Froeschl M, Zarate SB: Risperidone in the treatment of mania. Journal of Clinical Psychiatry 1996; 57:249–253
Ghaemi SN, Sachs GS, Baldassano C, Truman C: Acute treatment of bipolar disorder with adjunctive risperidone in outpatients. Canadian Journal of Psychiatry 1997; 42:196–199
Ghaemi SN, Sachs GS: Long-term risperidone treatment in bipolar disorder: 6 month follow-up. International Clinical Psychopharmacology 1998; 12:333–338
Dwight MM, Keck PE, Stanton SP, Strakowski SM, McElroy SL: Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder (letter). The Lancet 1994; 344:554–555
Sajatovic M, DiGiovanni SK, Bastani B, Hattab H, Ramirez LF: Risperidone therapy in treatment refractory acute bipolar and schizoaffective mania. Psychopharmacology Bulletin 1996; 32:55–61
Keck PE, Jr., Wilson DR, Strakowski SM, et al.: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. Journal of Clinical Psychiatry 1995; 56:466–471
Singh AN, Catalan J: Safety of risperidone in patients with HIV and AIDS. New York: American Psychiatric Association: 1996
Gilmer WS, Ferrando SJ, Goldman JD: Risperidone in the treatment of psychiatric symptoms in patients with AIDS. 148th American Psychiatric Association Annual Meeting, Miami, Florida, 1995
Horne RL, Miller F: Use of risperidone in a private psychiatric practice. 148th American Psychiatric Association Annual Meeting, Miami, Florida, 1995
Schaffer CB, Schaffer LC: The use of risperidone in the treatment of bipolar disorder (letter). Journal of Clinical Psychiatry 1996; 57:136
Tohen M, Sanger TM, Tollefson GD, McElroy SL: Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients. 2nd international conference on bipolar disorder, Pittsburgh, Pennsylvania, 1997
Tohen M, Snger T, Tollefson G, McElroy S, Greatney M, Toma V: Olanzapine vs. placebo in the treatment of acute mania (abstract). American College of Neuropsychopharmacology, Waikoloa, Hawaii, 1997, December
McElroy S, Frye M, Denicoff K, et al.: Olanzapine in treatment-resistant bipolar disorder. Journal of Affective Disorders 1998; 49:119–122
Zarate CA, Narendran R, Tohen M, et al.: Clinical predictors of acute response with olanzapine in psychotic mood disorders. Journal of Clinical Psychiatry 1998; 59:24–28
Ghaemi SN, Lee-Cherry ER, Katzow JJ, Goodwin FK: Olanzapine treatment of mood disorders. American Psychiatric Association annual meeting, Toronto, Ontario, 1998
Sachs G, et al.: Comparison of atypical antipsychotics in the treatment of bipolar disorder. Collegium Internationale Neuropsychopharmacologicum, Scotland, 1998
Casey D: The relationship of pharmacology to side effects. Journal of Clinical Psychiatry 1997; 58(suppl 10):55–62
Chouinard G, Arnott W: Clinical review of risperidone. Canadian Journal of Psychiatry 1993; 38(suppl 3):S89–S95
Novac A: The use of atypical antipsychotics in rapid-cycling bipolar disorder. Annals of Clinical Psychiatry 1998; 10:107–111
Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Research 1997; 73:159–171
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ghaemi, S.N., Katzow, J.J. The Use of Quetiapine for Treatment-Resistant Bipolar Disorder: A Case Series. Ann Clin Psychiatry 11, 137–140 (1999). https://doi.org/10.1023/A:1022307910520
Issue Date:
DOI: https://doi.org/10.1023/A:1022307910520